IMVT SEC filings, in plain English
Everything Health Sciences Acquisitions Corp has filed with the SEC that we hold — 40 filings, newest first, 4 with a plain-English summary of what changed and why it matters. Every row links to the primary document on EDGAR, so you can check the source rather than trust us.
The feed
live EDGAR captureNew filings appear here within minutes of hitting EDGAR; summaries follow once the pipeline has read them.
What changed: Immunovant, Inc. (Nasdaq: IMVT) filed its 10-Q for the quarter ended June 30, 2026, its fiscal first quarter, with 206,552,682 shares outstanding as of August 3, 2026. Cash and equivalents fell to $797,798 thousand from $902,110 thousand at March 31, 2026 and total assets to $852,490 thousand from $957,014 thousand, while accrued expenses and other current liabilities rose to $106,964 thousand from $96,881 thousand, taking total liabilities to $117,102 thousand. Total stockholders' equity fell to $735,388 thousand from $852,592 thousand and the accumulated deficit reached $1,898,353 thousand. Why it matters: Cash fell $104.3 million in a single quarter against a $153.2 million loss, the difference largely non-cash compensation and option proceeds. There is no debt on this balance sheet — total liabilities of $117.1 million are accruals and payables — so the runway is entirely a function of the burn rate, which rose 27% year over year.
What changed: Immunovant, Inc. (Nasdaq: IMVT) furnished a press release reporting results for its fiscal first quarter ended June 30, 2026. Cash and equivalents were $797.8 million, which the company states provides runway to the potential commercial launch of IMVT-1402 in Graves' disease based on its current operating plan. Why it matters: At $153.2 million a quarter, $797.8 million is roughly five quarters of spending, and the stated runway reaches a commercial launch whose enabling data does not arrive until calendar 2027 — the runway claim and the data timeline are the two facts to hold together. R&D rose 41% while G&A fell 32%, so the increase is trials, not overhead.
What changed: Immunovant, Inc., the successor to Health Sciences Acquisitions Corp, filed definitive additional proxy materials under Schedule 14A. The captured text is the SEC cover page only: it names Immunovant as registrant, marks the Definitive Additional Materials box rather than a preliminary or definitive proxy statement, and checks that no filing fee is required. No supplemental disclosure, exhibit text or revised proposal language is present in the captured document. Why it matters: Nothing here changes a trust balance, redemption right, deadline or vote recommendation, so there is no action for a holder. It should be read alongside Immunovant's definitive proxy for the September 2, 2026 annual meeting, which carries the actual proposals and the July 8, 2026 record date. Confidence is deliberately low because only the cover page was captured — whatever supplemental material prompted the filing is not visible, so this summary cannot describe its substance.(flagged for human review)
What changed: Immunovant, Inc., the successor to Health Sciences Acquisitions Corp, called its 2026 annual meeting for 2 September 2026, virtual, record date 8 July 2026. Three directors stand for election to the 2027 meeting: Jacob Bauer, Douglas Hughes and Robert Susman. The compensation tables value equity at the 31 March 2026 Nasdaq close of $24.84 per share. Why it matters: A routine annual meeting, but a useful marker: the successor to Health Sciences Acquisitions Corp is a functioning Nasdaq operating company whose stock closed at $24.84 on 31 March 2026, the outcome a sponsor track record should register. Note also a discrepancy in OUR record, not in the document: this CIK is stored with status LIQUIDATED while it is plainly filing as an operating Nasdaq company that completed its combination. A vehicle that completed a combination is not liquidated, and the status wants review.
In plain English
Redemption deadlinethe last day to hand shares back for cash
Set by the filing that calls the meeting. Tender after it and the company is under no obligation to pay you the trust value.
Cash in trust / trust per sharethe cash the company is holding for each public share
Filed quarterly in the 10-Q's XBRL. It earns interest between filings, so the figure on a given day is slightly higher than the last filed one — where we show that we label it an estimate.
Accession numberthe SEC's unique id for one filing
Every figure on this page carries the accession of the filing that states it, so you can open the primary document rather than trust us.